Estimating the cost of blood: past, present, and future directions

Shander, Aryeh; Hofmann, Axel; Gombotz, Hans; Theusinger, Oliver M.; Spahn, Donat R.

doi:10.1016/j.bpa.2007.01.002

Cited by 206 publications

(162 citation statements)

References 106 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…However, the predicted cost of transfusing a blood unit in the hospital per-RBC-unit is calculated between $522 and $1183 USD (mean, 761 ± 294) in recent studies [15,16]. In addition the cost of nursing staff and materials used to administer this unit is approximately $300 AUD at our hospital subject to a significant increase depending on occurrence of complications [16]. The cost of one iron sulphate tablet is approximately USD $0.2-0.3, so the average cost for 4 weeks is calculated to be $9.…”

Section: Cost-effectiveness Analysismentioning

confidence: 99%

A Prospective Randomized Controlled Trial to Assess the Effect of Intravenous versus Oral Iron Therapy in the Treatment of Preoperative Anaemia

Khalafallah¹,

Al-Barzan²,

Chan³

et al. 2012

J Blood Disord Transfus

View full text Add to dashboard Cite

Background: Improving preoperative anaemia is associated with a better surgical outcome. There is lack of data regarding treatment of preoperative anaemia with intravenous versus oral iron.Objective: Assessment of efficacy of oral iron sulphate versus a single intravenous iron polymaltose and subsequent effect on perceived quality of life in both treatment groups. Patients and methods:We conducted a prospective randomised controlled trial with iron therapy for the treatment of Iron Deficiency Anaemia (IDA) patients who were undergoing elective joint arthroplasty. At a single institution, we recruited 44 patients who were randomized to a single intravenous iron polymaltose infusion (16/22) versus oral daily iron sulphate (17/22). Median age was 68 years (range, 45-91) with a male to female ratio of 14:19.

show abstract

Section: Cost-effectiveness Analysismentioning

confidence: 99%

A Prospective Randomized Controlled Trial to Assess the Effect of Intravenous versus Oral Iron Therapy in the Treatment of Preoperative Anaemia

Khalafallah¹,

Al-Barzan²,

Chan³

et al. 2012

J Blood Disord Transfus

View full text Add to dashboard Cite

show abstract

“…Although blood transfusions have been associated with adverse outcomes, anemia is also associated with increased mortality rates [13][14][15][16] . The costs of blood transfusion are particularly complex to assess because of the many factors that have to be taken into consideration such as blood collection and screening for pathogens; blood component processing, including leuko reduction, storage, transport to the transfusion facility; administration of blood to the patient; management of potential short-and long-term transfusion-related side effects 10,17 .…”

Section: Introductionmentioning

confidence: 99%

Equilibration and Increase of Hemoglobin Concentration after One Unit Whole Blood Transfusion among Patients Not Actively Bleeding

Hoque

Adnan

Karim³

et al. 2015

J Dhaka Med Coll

View full text Add to dashboard Cite

show abstract

“…Disease transmission and adverse reactions from misstransfusions remain problematic even with best practices in place (30,103,129,133,161). These and other factors have led to a cost explosion in the industry (105), with the price of blood units increasing significantly in recent years (7,11,134).…”

mentioning

confidence: 99%

Development of Recombinant Hemoglobin-Based Oxygen Carriers

Varnado

Mollan

Birukou

et al. 2013

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

Significance: The worldwide blood shortage has generated a significant demand for alternatives to whole blood and packed red blood cells for use in transfusion therapy. One such alternative involves the use of acellular recombinant hemoglobin (Hb) as an oxygen carrier. Recent Advances: Large amounts of recombinant human Hb can be expressed and purified from transgenic Escherichia coli. The physiological suitability of this material can be enhanced using protein-engineering strategies to address specific efficacy and toxicity issues. Mutagenesis of Hb can (i) adjust dioxygen affinity over a 100-fold range, (ii) reduce nitric oxide (NO) scavenging over 30-fold without compromising dioxygen binding, (iii) slow the rate of autooxidation, (iv) slow the rate of hemin loss, (v) impede subunit dissociation, and (vi) diminish irreversible subunit denaturation. Recombinant Hb production is potentially unlimited and readily subjected to current good manufacturing practices, but may be restricted by cost. Acellular Hb-based O 2 carriers have superior shelf-life compared to red blood cells, are universally compatible, and provide an alternative for patients for whom no other alternative blood products are available or acceptable. Critical Issues: Remaining objectives include increasing Hb stability, mitigating iron-catalyzed and iron-centered oxidative reactivity, lowering the rate of hemin loss, and lowering the costs of expression and purification. Although many mutations and chemical modifications have been proposed to address these issues, the precise ensemble of mutations has not yet been identified. Future Directions: Future studies are aimed at selecting various combinations of mutations that can reduce NO scavenging, autooxidation, oxidative degradation, and denaturation without compromising O 2 delivery, and then investigating their suitability and safety in vivo. Antioxid. Redox Signal. 18, 2314-2328.

show abstract

Estimating the cost of blood: past, present, and future directions

Cited by 206 publications

References 106 publications

A Prospective Randomized Controlled Trial to Assess the Effect of Intravenous versus Oral Iron Therapy in the Treatment of Preoperative Anaemia

A Prospective Randomized Controlled Trial to Assess the Effect of Intravenous versus Oral Iron Therapy in the Treatment of Preoperative Anaemia

Equilibration and Increase of Hemoglobin Concentration after One Unit Whole Blood Transfusion among Patients Not Actively Bleeding

Development of Recombinant Hemoglobin-Based Oxygen Carriers

Contact Info

Product

Resources

About